首页> 美国卫生研究院文献>BMC Pharmacology Toxicology >Cotrimoxazole plasma levels dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations
【2h】

Cotrimoxazole plasma levels dialyzer clearance and total removal by extended dialysis in a patient with acute kidney injury: risk of under-dosing using current dosing recommendations

机译:急性肾损伤患者的复方克曲莫唑血浆水平透析仪清除率和经长期透析后的总清除量:使用当前剂量推荐的剂量不足风险

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDosing of antibiotics in critically ill patients is challenging. It becomes even more difficult if renal or hepatic impairment ensue. Modern means of renal replacement therapy are capable of removing antibiotics to a higher rate than decades ago, leaving clinicians with a high degree of uncertainty concerning the dose of antibiotics in this patient population. Cotrimoxazole, a combination of trimethoprim (TMP) and sulfamethoxazole (SMX) is frequently used in the treatment of several infections including Pneumocystis jirovecii pneumonia (PCP).
机译:背景技术在危重病人中使用抗生素具有挑战性。如果随后出现肾脏或肝功能损害,则变得更加困难。肾脏替代疗法的现代手段能够以比几十年前更高的速率去除抗生素,这给临床医生在该患者人群中抗生素剂量方面带来了高度不确定性。复方新诺明(复方新诺明(TMP)和磺胺甲基异恶唑(SMX)的组合)经常用于治疗包括吉氏肺孢子虫肺炎(PCP)在内的几种感染。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号